TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: changes of 24-hour ambulatory systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Corrected QT (QTc) Interval Greater Than or Equal to 500 Millisecond
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of subtle damage to kidneys
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of subtle damage to eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: abnormal glucose handling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lung ultrasound artifacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma curcumin metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Urinary Sodium Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function Improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fusion Prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Go/No-go Task Performance Correct Inhibitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Go/No-go Task Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Go/No-go Task Performance Correct Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ANRIL production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epigenetic marks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate to severe MBS/FEES Dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rheobase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: polyp detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients agreeing to undergo HIV screening test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients who developed encephalopathy
Endpoint domain: Adverse events/effects
Primary endpoint: Development of Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of ischemic stroke and recurrent intracerebral hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of CVA patients with symptom relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Delirium assessment using CAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence with ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial oxygen pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygen reserve index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in renal sodium chloride excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Skin cooling during laser treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Central nervous system metastasis development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline of Kinematic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difference between calibrated measurements and reference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Medication Discrepancies
Endpoint domain: Adverse events/effects
Primary endpoint: Subacute toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Walter Reed Visual Assessment (WRVAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coopersmith Self-Esteem Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scoliosis Research Society-22
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Scoliosis Treatment Compliance Scale
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: safety and tolerability of bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Behavioral Avoidance Test (BAT)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decline in dominant fibroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Erythroid Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy Assessed Using the Inventory of Depressive Symptomatology - Clinician Rated (IDS-C)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Adverse Events (Physical Symptoms) Emerging or Worsening During 12 Weeks of Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Non-relapse Mortality at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Chronic Graft Versus Host Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Grades III/IV Acute Graft Versus Host Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Excessive weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infarct size and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gait ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Competence in basic ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: maximum observed serum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Procollagen Type 1 N-terminal Propeptide (P1NP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of adults with PCR confirmed influenza tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in the Modified Crohn's Disease Activity Index (mCDAI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of unknown atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hours of NIPPV Usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Mean iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postponing delivery for 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in cervical length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strokes, Either Fatal or Nonfatal
Endpoint domain: Mortality/survival
Primary endpoint: Physiological modifications during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid Stimulating Hormone (TSH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Respiratory resistance at 5Hz - 20Hz (R5-R20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expiratory phase low attenuation area <856 HU (%LAA <856 HU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee-extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biopsyproven rejection
Endpoint domain: Mortality/survival
Primary endpoint: Progression of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Left Ventricular Mass Indexed to Height (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood biochemical value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of recorded infections including viral opportunistic infection
Endpoint domain: Adverse events/effects
Primary endpoint: Saturation percentage of α4β1integrin receptors on the surface of lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Difference in neutrophil CD64 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in CD4+ T cell TLR2 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in GILT expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in the Most Bothersome Vulvar and Vaginal Atrophy Symptom of Vaginal Dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in the Most Bothersome Symptom of Vaginal Pain Associated With Sexual Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with MDI misuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delivery within 48 hours
Endpoint domain: Mortality/survival
Primary endpoint: Crohn's Disease Activity Index (CDAI) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance (Cl/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clearance during dialysis (CLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fraction of total clearance attributed to dialysis (FD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time required for successful intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in T regulatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants with Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of recruitment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of intervention completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of measurement completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage change in urgency episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/tolerability of BYK324677
Endpoint domain: Adverse events/effects
Primary endpoint: Bleeding score assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Subjects With DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of AR100DP1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With the Investigator's Global Assessment (IGA) Score of 0 or 1 on Day 29
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Calves muscle quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Physiological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea Management Questionnaire Computer Adaptive Test (DMQ-CAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Daptomycin Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of New Onset Diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Default Mode Network Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Error Positivity (Pe)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Prostaglandin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: McGill Pain Questionnaire (change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale for Pain (change)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of Major Adverse Cardiac Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: clinical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: histological recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Focused attention performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Performance-based Function: Heel Raises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Thresholds via QST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of radial artery occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tolerability of Medications
Endpoint domain: Adverse events/effects
Primary endpoint: HMGA2 protein concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events caused by EMS
Endpoint domain: Adverse events/effects
Primary endpoint: Haemophilia care improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemophilia diagnosis improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about haemophilia improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symmetry Index of Pelvic Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation free days at D28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total phosphorus bound and entrapped per piece of chewing gum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time spent in any activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cross-sectional Area of Skeletal Muscle Fibers (All Fibers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Calcium-activated Tension Single Muscle Fiber Tension (Myosin Heavy Chain (MHC) IIA Fibers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Single Muscle Fiber Shortening Velocity (Myosin Heavy Chain (MHC) IIA Fibers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to closure of the epithelial wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cardiotoxicity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Number of Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gilbert Joint Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Haemophilia Joint Health Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants Completing Entire Intervention Protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change in Forearm Blood Flow (FBF) Response to BQ-123 (100 Nmol/Min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical outcomes after total knee replacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vulvar-cancer-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Completeness of reporting
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants with Adverse events (AEs) and serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With TIMI Major/Minor Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With GUSTO Severe/Moderate Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Intracranial Hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Chemistry and Hematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Point Prevalence of 7-day Tobacco Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Abstinence at the 12-week Follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Solid fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Added sugar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-starchy vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole fruit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole grains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total number of T cells recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Alpha diversity changes of fecal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta diversity changes of fecal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in aggression and agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight loss of at least 3%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Freedom from Major Adverse Events (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of electrical source localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Confirmed Perceptible Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea and vomiting severity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: LHRH-agonist-related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maximum observed plasma concentration (Cmax) of MT-7117
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from time zero to the last quantifiable concentration (AUC0-last) of MT-7117
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from time zero to infinity (AUC0-∞) of MT-7117
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache days change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve; AUC_0-∞
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC τ,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (Peak Concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of the ulcer reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Revision Rate
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in the Mean BMI at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes